Introduction: SARS-COV2 infection is a major public health problem and diabetes
mellitus is a serious factor. The objective was to determine the characteristics of COVID-19 in diabetics at the
Epidemic Treatment Center (ETC) of the Abass Ndao Hospital Center. Observation: This was a retrospective, descriptive and
analytical study carried out at Abass Ndao Hospital from March 01, 2021 to September 31, 2021. We evaluated
the epidemiological, clinical and evolutionary characteristics. Results: Among 333 patients infected with COVID-19, 203 were diabetic (60.96%). The sex
ratio was 0.70 and the mean age 60.18 years.
Diabetes was type 2 (84.2%) and inaugural (15.8%). Arterial hypertension
was the main comorbidity (86.96% of cases). The
RT-PCR test was positive in 86.21% of cases. The main clinical signs
were: asthenia (90.14%), dyspnea (78.81%),
cough (52.21%) and body aches (52.21%). Oxygen saturation was <90% in 31.03% of cases. Diabetes was poorly balanced
in 71.43% with an average blood sugar of 2.02 ± 4 g/l. At the paraclinical, the D dimer was ≥1000 ng/l (71.52%) and the
C-reactive protein ≥100 mg/l (32.01%). Chest CT scan found mild to moderate
(55.17%), severe (21.67%) and critical (17.24%) lung lesions. Pulmonary
embolism was found in 4 diabetics. The
treatment of diabetes was represented by insulin therapy (85.82%) and
oral antidiabetics (24.11%). Anti-COVID-19 treatment was dominated by
azithromycin (89.11%), corticosteroid therapy (92.11%), anticoagulants (99%),
hydroxychloroquine (21.29%). Mortality was found in 14.36% (n=29) and significantly correlated with age ≥ 60 years
(OR = 3.013[1.266-7.173], P = 0.005), short duration of
hospitalization (OR = 3.154[1.149-
References
[1]
OMS (World Health Organization) (2020) Stratégie de réponse COVID-19—Diabète 2020. World Health Organization, Geneva, 143.
[2]
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J.J.V., Pfeffer, M.A. and Solomon, S.D. (2020) Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. The New England Journal of Medicine, 382, 1653-1659. https://doi.org/10.1056/NEJMsr2005760
[3]
Wan, Y., Shang, J., Graham, R., Baric, R.S. and Li, F. (2020) Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. Journal of Virology, 94, e00127-20. https://doi.org/10.1128/JVI.00127-20
[4]
Chhabra, K.H., Chodavarapu, H. and Lazartigues, E. (2013) Angiotensin Converting Enzyme 2: A New Important Player in the Regulation of Glycemia. IUBMB Life, 65, 731-738. https://doi.org/10.1002/iub.1190
[5]
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., et al. (2020) Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. The Lancet Respiratory Medicine, 8, 475-481. https://doi.org/10.1016/S2213-2600(20)30079-5
[6]
Zhang, J.J., Dong, X., Cao, Y.Y., Yuan, Y.D., Yang, Y.B., Yan, Y.Q., et al. (2020) Clinical Characteristics of 140 Patients Infected with SARS-CoV-2 in Wuhan, China. Allergy, 75, 1730-1741. https://doi.org/10.1111/all.14238
[7]
CDC COVID-19 Response Team (2020) Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019—United States, February 12-March 28, 2020. Morbidity and Mortality Weekly Report, 69, 382-386. https://doi.org/10.15585/mmwr.mm6913e2
[8]
Cariou, B., Hadjadj, S., Wargny, M., Pichelin, M., Al-Salameh, A., Allix, I., et al. (2020) Phenotypic Characteristics and Prognosis of Inpatients with COVID-19 and Diabetes: The CORONADO Study. Diabetologia, 63, 1500-1515. https://doi.org/10.1007/s00125-020-05180-x
[9]
Cariou, B., Gourdy, P., Hadjadj, S., Pichelin, M. and Wargny, M. (2021) Diabète et COVID-19: Les leçons de CORONADO. Médecine des Maladies Métaboliques, 15, 15-23. https://doi.org/10.1016/j.mmm.2020.12.010
[10]
Traoré, B., Coulibaly, M.B. and Mariko, M. (2021) Infection à Covid 19 et Diabète à l’Hôpital du Mali (Bamako). Health Sciences and Disease, 22, 9-12.
[11]
Donamou, J., Bangoura, A., Camara, L.M., Camara, D., Traoré, D.A., Abékan, R.J.-M., et al. (2021) Caractéristiques épidémiologiques et cliniques des patients COVID-19 admis en réanimation à l’hôpital Donka de Conakry, Guinée: Etude descriptive des 140 premiers cas hospitalisés. Anesthésie & Réanimation, 7, 102-109. https://doi.org/10.1016/j.anrea.2021.01.001
[12]
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., et al. (2020) Covid-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA, 323, 1574-1581. https://doi.org/10.1001/jama.2020.5394
[13]
Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention (2020) Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. Chinese Journal of Epidemiology, 41, 145-151.
[14]
Fosse-Edorh, S. and Mandereau-Bruno, L. (2021) Hospitalisations pour Covid-19 au 1er semestre 2020 chez les personnes traitées pharmacologiquement pour un diabète en France. Bulletin épidémiologique Hebdomadaire, 2-8. http://beh.santepubliquefrance.fr/beh/2021/Cov_4/2021_Cov_4_1.html
[15]
Sathish, T., Kapoor, N., Cao, Y., Tapp, R.J. and Zimmet, P. (2021) Proportion de diabète nouvellement diagnostiqué chez les patients COVID-19: Une revue systématique et une méta-analyse. Diabetes, Obesity and Metabolism, 23, 870-874
[16]
Khunti, K., Del Prato, S., Mathieu, M., Kahn, S.E., Gabbay, R.A. and Buse, J.B. (2021) COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care, 44, 2645-2655. https://doi.org/10.2337/dc21-1318
[17]
Guan, W., Ni, Z., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine, 382, 1708-1720. https://doi.org/10.1056/NEJMoa2002032
[18]
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., et al. (2020) Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine, 180, 934-943. https://doi.org/10.1001/jamainternmed.2020.0994
[19]
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et al. (2020) Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. The Lancet, 395, 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
[20]
Fuentes, S., Mandereau-Bruno, L., Regnault, N., Bernillon, P., Bonaldi, C., Cosson, E., et al. (2020) Is the Type 2 Diabetes Epidemic Plateauing in France? A Nationwide Population-Based Study. Diabetes & Metabolism, 46, 472-479. https://doi.org/10.1016/j.diabet.2019.12.006
[21]
Ketfi, A., Chabati, O., Chemali, S., Mahjoub, M., Gharnaout, M., Touahri, R., et al. (2020) Profil clinique, biologique et radiologique des patients algériens hospitalisés pour COVID-19: Données préliminaires. Pan African Medical Journal, 35, Article No. 77. https://doi.org/10.11604/pamj.supp.2020.35.2.23807
[22]
Chakafana, G., Mutithu, D., Hoevelmann, J., Ntusi, N. and Sliwa, K. (2020) Interplay of Covid-19 and Cardiovascular Diseases in Africa: An Observational Snapshot. Clinical Research in Cardiology, 109, 1460-1468. https://doi.org/10.1007/s00392-020-01720-y
[23]
Seiglie, J., Platt, J., Cromer, S.J., Bunda, B., Foulkes, A.S., Bassett, I.V., et al. (2020) Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized with COVID-19. Diabetes Care, 43, 2938-2944. https://doi.org/10.2337/dc20-1506
[24]
Paquot, N. and Radermecker, R.P. (2020) Covid-19 et diabète. Revue medicale de Liege, 75, 138-145.
[25]
Petrilli, C.M., Jones, S.A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., et al. (2020) Factors Associated with Hospital Admission and Critical Illness among 5279 People with Coronavirus Disease 2019 in New York City: Prospective Cohort Study. BMJ, 369, m1966. https://doi.org/10.1136/bmj.m1966
[26]
Ouedraogo, E., Lucie, A., Sutton, A., Didier, M., Giroux-Leprieur, B., Deutsch, D., et al. (2020) Syndrome métabolique et COVID-19: Quel risque de pneumopathie sévère? Médecine et maladies infectieuses, 50, S85. https://doi.org/10.1016/j.medmal.2020.06.171
[27]
Lounici, A., Benmekki, A., Ghenou, A., Tahir, S., Belmimoune, A., Zini, S., et al. (2021) Particularités cliniques des patients diabétiques hospitalisés pour Covid-19 sur une période d’une année. Revue Algérienne d’allergologie et d’immunologie clinique, 6, 2543-3555.
[28]
Kokkinakis, I., Selby, K., Favrat, B., Genton, B. and Cornuz, J. (2020) Performance du frottis nasopharyngé-PCR pour le diagnostic du Covid-19—Recommandations pratiques sur la base des premières données scientifiques. Revue Médicale Suisse, 6, 699-701. https://doi.org/10.53738/REVMED.2020.16.689.0699
[29]
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. Lancet, 395, 507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
[30]
Kanne, J.P. (2020) Chest CT Findings in 2019 Novel Coronavirus (2019-nCoV) Infections from Wuhan, China: Key Points for the Radiologist. Radiology, 295, 16-17. https://doi.org/10.1148/radiol.2020200241
[31]
Ba, M., Toure, N.O., Fortes, L., et al. (2021) Atelier préparatoire de la mission d’orientation des personnels des régions médicales pour la prise en charge à domicile (PECADOM) des cas de COVID-19. Somone 28-29-30 Janvier 2021.
[32]
Zhang, J.J.Y., Lee, K.S., Ang, L.W., Leo, Y.S. and Young, B.E. (2020) Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected with COVID-19: A Systematic Review, Meta-Analysis and Meta Regression Analysis. Clinical Infectious Diseases, 71, 2199-2206. https://doi.org/10.1093/cid/ciaa576
[33]
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., et al. (2020) Risk Factors of Critical & Mortal COVID-19 Cases: A Systematic Literature Review and Meta-Analysis. Journal of Infection, 81, E16-E25. https://doi.org/10.1016/j.jinf.2020.04.021
